Boston Scientific shares tumble to 52-week low amid analyst downgrades
Boston Scientific (BSX) has faced a mixed week as analysts adjust their outlooks. The company's shares recently hit a 52-week low, trading at around $65.26. Despite this dip, some firms still see long-term potential in the medical device maker.
The latest shifts come after new FDA clearance and trial results, but growth concerns have prompted rating changes. Raymond James cut its rating on BSX from Strong Buy to Outperform, lowering the price target from $97 to $88. The firm also trimmed its 2026 and 2027 revenue forecasts by roughly 0.5% and 1.5%, respectively. These adjustments reflect worries about slowing growth in U.S. electrophysiology and the Watchman product line.
Yet, not all analysts are pulling back. Stifel kept its Buy recommendation with a $90 target, while Evercore ISI and Bernstein maintained Outperform ratings. The company's fundamentals remain strong, with nearly 20% revenue growth over the past year and a PEG ratio of 0.64.
On the regulatory front, BSX recently secured FDA 510(k) clearance for its Asurys fluid management system. The CHAMPION-AF trial also met its primary endpoints for the Watchman device, reinforcing its position in the market. Still, shares have dropped by about 30% over the last 12 months, pushing the stock near annual lows.
With a market capitalisation of approximately $102.8 billion, BSX remains a major player. However, the recent decline highlights investor caution amid shifting analyst expectations. Boston Scientific continues to expand its product portfolio with new clearances and trial successes. Yet, the stock's decline and revised forecasts suggest a period of uncertainty. The company's next steps will determine whether it can regain momentum in a competitive medical device market.
